{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:09:11Z","timestamp":1783976951873,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eururo.2026.06.025","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:26:08Z","timestamp":1783974368000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http:\/\/dx.doi.org\/10.1016\/j.eururo.2026.03.014"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-5746","authenticated-orcid":false,"given":"Isabel","family":"Heidegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.06.025_b0005","unstructured":"Cavka L, Nandakumar S, Wu Q, et al. IDH1 mutations are associated with favorable outcomes in prostate cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2026.03.014."},{"key":"10.1016\/j.eururo.2026.06.025_b0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2026.06.025_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100616","article-title":"Histopathologic and molecular characterization of IDH-mutant prostatic adenocarcinoma","volume":"38","author":"Samueli","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.06.025_b0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.025_b0025","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, Phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.025_b0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.025_b0035","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2026.06.025_b0040","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.06.025_b0045","article-title":"Molecular subtypes of prostate cancer and their clinical implications","author":"Weiner","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.025_b0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fonc.2017.00131","article-title":"The metabolic phenotype of prostate cancer","volume":"7","author":"Eidelman","year":"2017","journal-title":"Front Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826022578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:26:10Z","timestamp":1783974370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826022578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":10,"alternative-id":["S0302283826022578"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.025","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Luka Cavka, Subhiksha Nandakumar, Qingqing Wu, et al. IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer. Eur Urol. In press. http:\/\/dx.doi.org\/10.1016\/j.eururo.2026.03.014","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}